Sign in
Taking peoplePhase 3

Tests lemborexant for sleep problems in people with epilepsy

Tests whether lemborexant improves sleep in adults with epilepsy.

Key facts

Who runs it
University of Manitoba
Where
Durham, United StatesSee the siteAlso in 1 other country, 1 site
Trial code
Registry title
Lemborexant Treatment of Insomnia Linked to Epilepsy
Status
Recruiting
Phase
Phase 3
People taking part
26 people, planned
Started
29 Oct 2024
Expected to end
18 Apr 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Lemborexant
  • Placebo
Record updated
13 February 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with epilepsy linked to sleep, to see whether Lemborexant can improve their sleep.

Age
18 years or older
Sex
Men and women can join.
Disease stage
Sleep-related focal epilepsy.
Earlier treatment
Antiseizure medication must not have been changed in the month before the study or during it.

Main reasons for not taking part

  • Pregnant or breastfeeding women
  • Liver problems (hepatic impairment)
  • Breathing problems (compromised respiratory function)
  • History of complex sleep-related behaviour
  • Psychiatric disorders with abnormal thinking, depression or suicidal thoughts

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Sleep-related focal epilepsy
  • Contraception

Who cannot take part

  • Changes in antiseizure medication 1 month before study protocol or during study protocol
  • Concomitant medications per SUNRISE1
  • Individuals with hepatic impairment
  • Individuals with a history of complex sleep-related behaviour
  • Individuals with a history of dependence or tolerance - abuse, dependence, rebound insomnia
  • Individuals with psychiatric disorders with abnormal thinking and behavioural changes, depression, or suicidal ideation
  • Individuals with rare hereditary diseases of galactose intolerance such as galactosemia or glucose-galactose malabsorption
  • Female participants who are pregnant or breastfeeding
  • Individuals with compromised respiratory function
  • Individuals with a diagnosis of narcolepsy

Where in United States

Also in 1 other country, 1 site

  • Duke UniversityDurham, United StatesContact: Birgit Frauscher, MD, PhDNot yet recruiting

About the trial

What the trial wants to find out

The goal of this clinical trial is to assess whether Lemborexant can improve sleep in patients with epilepsy.

The 2 groups in the trial

  • Placebo FirstPlacebo, for comparison

    0mg

    Treatment: Lemborexant and Placebo

  • Investigational Product FirstExisting treatment, for comparison

    10mg qhs

    Treatment: Lemborexant and Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Lemborexant Treatment of Insomnia Linked to Epilepsy
Plain-language title
Tests lemborexant for sleep problems in people with epilepsyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
13 February 2025